API
< Back to situations

[ORGANIZATION]

CagriSema

Featured in 10 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [US] [DK] [BR]

Novo Nordisk raises 2026 outlook on Wegovy demand

117 clusters · 557 sources · last updated

Latest: Omada Health and Novo Nordisk present new obesity treatment data

Novo Nordisk is navigating market volatility and patent risks, specifically the potential for generic competition as U.S. patents for its primary active ingredients expire in 2032. While the company faces intense competi

[ACTIVE] [HEALTH] [US] [BR] [IT]

GLP-1 receptor agonist research and safety scrutiny

13 clusters · 72 sources · last updated

Latest: GLP-1 medications face scrutiny over vision loss risks and clinical developments

Research into GLP-1 receptor agonists (GLP-1 RAs) has expanded to investigate health benefits beyond glycemic control and weight loss, specifically regarding bone health, pain, and inflammation. Studies involving adults

[ACTIVE] [HEALTH] [DK] [BR] [US]

Novo Nordisk CagriSema clinical trial results

3 clusters · 13 sources · last updated

Latest: Novo Nordisk reports weight loss data for Wegovy and CagriSema

Novo Nordisk has released findings from Phase 3 clinical trials regarding its experimental medication, CagriSema, which combines cagrilintide and semaglutide to treat diabetes and obesity. Initial results from the Phase